Physician profile
Joseph Gigante
NPI 1720068430
$1,867.46
in general payments reported to CMS, 2019-2025
22 companies · $355 in 2025
The $355 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $218 · 2020: $338 · 2021: $132 · 2022: $171 · 2023: $283 · 2024: $371 · 2025: $355.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,010.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,009.52 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $320.32 | 2019-2020 | |
| Abbott Laboratories | $274.72 | 2022-2025 | Freestyle Libre 3 |
| Astrazeneca Pharmaceuticals LP | $201.56 | 2022-2024 | Airsupra |
| Pfizer INC. | $141.78 | 2019-2025 | |
| Abbvie INC. | $140.67 | 2021-2025 | |
| Novartis Pharmaceuticals Corporation | $93.72 | 2019-2022 | |
| Lilly USA, LLC | $89.30 | 2020-2025 | Mounjaro, Zepbound |
| Otsuka America Pharmaceutical, INC. | $78.44 | 2023-2024 | Rexulti |
| Glaxosmithkline, LLC. | $69.72 | 2021-2023 | Trelegy Ellipta |
| Xeris Pharmaceuticals, INC. | $65.27 | 2025 | Recorlev |
| Amarin Pharma, INC. | $53.23 | 2020 | |
| Janssen Pharmaceuticals, INC | $52.36 | 2021-2023 | Xarelto |
| Daiichi Sankyo INC. | $49.82 | 2020-2024 | Injectafer |
| Astellas Pharma US INC | $37.69 | 2023 | Veozah |
| Novo Nordisk INC | $35.26 | 2023-2025 | Rybelsus, Ozempic |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $32.71 | 2019-2023 | Vaxneuvance, Pneumovax 23, Gardasil 9 |
| Kowa Pharmaceuticals America, INC. | $25.54 | 2019-2020 | |
| Idorsia Pharmaceuticals US INC | $24.44 | 2023 | Quviviq |
| E.R. Squibb & Sons, L.L.C. | $22.15 | 2024 | Eliquis |
| Dexcom, INC. | $21.81 | 2023 | Dexcom G6 Transmitter |
| Seqirus USA INC | $19.13 | 2022 | |
| Alexion Pharmaceuticals, INC. | $17.82 | 2025 | Koselugo |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Joseph Gigante listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.